FDA's liquid biopsy approval is a milestone for Guardant Health AMEA: CEO

In this video

Share

FDA's liquid biopsy approval is a milestone for Guardant Health AMEA: CEO

Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid biopsy approval that can help in cancer detection and treatment.
03:33
Fri, Sep 25 202012:14 AM EDT